Am. J. Respir. Crit. Care Med., Volume 161, Number 6, June 2000, 1991-1998

Insulinlike Growth Factor-1 in Lung Transplants with Obliterative Bronchiolitis

JEAN-MARIE CHARPIN, MARC STERN, DOMINIQUE GRENET, and DOMINIQUE ISRAËL-BIET

Laboratoire d'Immunologie Pulmonaire and Service de Pneumologie, Hôpital Laënnec, Paris; Service de Pneumologie, Hôpital Foch, Suresnes, France

Bronchiolitis obliterans syndrome (BOS) is the major complication limiting survival of lung transplant recipients (Tx patients). The mechanisms underlying this fibrotic process are not known. We assessed IGF-1 and IGFBP-3 expression, critical mediators in different models of pulmonary fibrosis, in nine Tx patients. Three of them developed a BOS at 8, 14, and 17 mo postgraft, respectively. Two of the remaining six displayed a recurrent cytomegalovirus (CMV) infection, and four are in stable condition. IGF-1 mRNA expression was quantitated by RT-PCR in cells from four to six BAL per patient performed during the first 6 mo postgraft. Contrasting with a constantly low expression of IGF-1 mRNA in BAL cells from the six patients without BOS, the three patients with BOS presented marked peaks of IGF-1 on two to five occasions during the study period. These peaks, 3- to 13-fold increased compared with values from the former patients, preceded the diagnosis of BOS by 7, 13, and 17 mo, respectively. On the other hand, IGFBP-3 was highly and exclusively expressed in the three patients with BOS, the mRNA as well as the gene product as demonstrated by Western blotting. Our data strongly argue for a role of IGF-1 and IGFBP-3 in the fibrotic process underlying BOS, and for their possible value as an early marker of this complication.

This article has been cited by other articles:

				D. M. Murphy, I. A. Forrest, P. A. Corris, G. E. Johnson, T. Small, D. Jones, A. J. Fisher, J. J. Egan, T. E. Cawston, C. Ward, et al. Simvastatin attenuates release of neutrophilic and remodeling factors from primary bronchial epithelial cells derived from stable lung transplant recipients Am J Physiol Lung Cell Mol Physiol, March 1, 2008; 294(3): L592 - L599. [Abstract] [Full Text] [PDF]

				J. D. Lande, J. Patil, N. Li, T. R. Berryman, R. A. King, and M. I. Hertz Novel Insights into Lung Transplant Rejection by Microarray Analysis Proceedings of the ATS, January 1, 2007; 4(1): 44 - 51. [Abstract] [Full Text] [PDF]

				B. S. Lu, A. D. Yu, X. Zhu, E. R. Garrity Jr, W. T. Vigneswaran, and S. M. Bhorade Sequential gene expression profiling in lung transplant recipients with chronic rejection. Chest, September 1, 2006; 130(3): 847 - 854. [Abstract] [Full Text] [PDF]

				L. P. Nicod Mechanisms of airway obliteration after lung transplantation. Proceedings of the ATS, July 1, 2006; 3(5): 444 - 449. [Abstract] [Full Text] [PDF]

				A. Boehler and M. Estenne Post-transplant bronchiolitis obliterans Eur. Respir. J., December 1, 2003; 22(6): 1007 - 1018. [Abstract] [Full Text] [PDF]

				O. Ibrahim-Granet, B. Philippe, H. Boleti, E. Boisvieux-Ulrich, D. Grenet, M. Stern, and J. P. Latge Phagocytosis and Intracellular Fate of Aspergillus fumigatus Conidia in Alveolar Macrophages Infect. Immun., February 1, 2003; 71(2): 891 - 903. [Abstract] [Full Text] [PDF]

				M. Estenne and M. I. Hertz Bronchiolitis Obliterans after Human Lung Transplantation Am. J. Respir. Crit. Care Med., August 15, 2002; 166(4): 440 - 444. [Full Text] [PDF]

				R. M. Aris, S. Walsh, W. Chalermskulrat, V. Hathwar, and I. P. Neuringer Growth Factor Upregulation during Obliterative Bronchiolitis in the Mouse Model Am. J. Respir. Crit. Care Med., August 1, 2002; 166(3): 417 - 422. [Abstract] [Full Text] [PDF]

				M. J. TOBIN Chronic Obstructive Pulmonary Disease, Pollution, Pulmonary Vascular Disease, Transplantation, Pleural Disease, and Lung Cancer in AJRCCM 2000 Am. J. Respir. Crit. Care Med., November 15, 2001; 164(10): 1789 - 1804. [Full Text] [PDF]